2024
Spatial Multiomics Profiling of Angioimmunoblastic T-Cell Lymphoma
Enninful A, Foss F, Fan R, Xu M. Spatial Multiomics Profiling of Angioimmunoblastic T-Cell Lymphoma. Blood 2024, 144: 1585-1585. DOI: 10.1182/blood-2024-211129.Peer-Reviewed Original ResearchAngioimmunoblastic T-cell lymphomaT follicular helper cellsT-cell lymphomaFollicular dendritic cellsHigh endothelial venulesT cellsTumor cellsTumor microenvironmentB cellsImmune surveillanceMultiplex immunofluorescenceCD21+ follicular dendritic cellsTumor evasion of immune surveillanceNon-neoplastic T cellsEvasion of immune surveillanceEBV-positive B cellsGene activity scoreTissue blocksActivity of tumor cellsReactive B cellsExpression of LMP1Positive B cellsComplex tumor microenvironmentT cell zonesLymph node sampling
2018
A Phase I Dose‐Escalation Study of Clofarabine in Patients with Relapsed or Refractory Low‐Grade or Intermediate‐Grade B‐Cell or T‐Cell Lymphoma
Foss FM, Parker T. A Phase I Dose‐Escalation Study of Clofarabine in Patients with Relapsed or Refractory Low‐Grade or Intermediate‐Grade B‐Cell or T‐Cell Lymphoma. The Oncologist 2018, 23: 397-e30. PMID: 29438091, PMCID: PMC5896711, DOI: 10.1634/theoncologist.2017-0658.Peer-Reviewed Original ResearchConceptsCutaneous T-cell lymphomaT-cell lymphomaNon-Hodgkin lymphomaOverall response rateIntermediate-grade B-cellB cellsPartial responseResponse ratePhase I dose-escalation studyRefractory acute lymphoblastic leukemiaI dose-escalation studyT-cell non-Hodgkin lymphomaB-cell non-Hodgkin lymphomaPositron emission tomography scanSecond-generation purine nucleoside analogAggressive B-cell lymphomasPhase IDose of clofarabineGrade 3 leukopeniaLow-dose cohortMinimal hematologic toxicityRefractory acute leukemiaRefractory low gradeRefractory lymphoid malignanciesSingle-agent rituximab
2010
Role of denileukin diftitox in the treatment of persistent or recurrent cutaneous T-cell lymphoma
Lansigan F, Stearns DM, Foss F. Role of denileukin diftitox in the treatment of persistent or recurrent cutaneous T-cell lymphoma. Cancer Management And Research 2010, Volume 2: 53-59. PMID: 21188096, PMCID: PMC3004568, DOI: 10.2147/cmar.s5009.Peer-Reviewed Original ResearchCutaneous T-cell lymphomaRecurrent cutaneous T-cell lymphomaTreatment of patientsT-cell lymphomaDenileukin diftitoxFusion protein toxinsT cellsCytocidal agentsRare lymphoproliferative disorderPivotal clinical trialsMalignant T cellsBiological response modifiersQuality of lifeMechanism of actionCD25 subunitCommon toxicitiesProgressive lymphomaLymphoproliferative disordersClinical trialsResponse modifiersIL2 receptorTraditional chemotherapyDiftitoxB cellsFDA approval
2006
Clinical Experience With Denileukin Diftitox (ONTAK)
Foss F. Clinical Experience With Denileukin Diftitox (ONTAK). Seminars In Oncology 2006, 33: 11-16. PMID: 16516670, DOI: 10.1053/j.seminoncol.2005.12.017.Peer-Reviewed Original ResearchConceptsIL-2 receptorCutaneous T-cell lymphomaT-cell lymphomaDenileukin diftitoxIntermediate affinity IL-2 receptorsHuman IL-2 receptorChronic lymphocytic leukemiaActivated T lymphocytesDiphtheria toxinClinical profileHodgkin's lymphomaHematologic disordersT lymphocytesLymphocytic leukemiaB cellsClinical experienceB lymphocytesLymphomaCytocidal actionNumber of leukemiasDiftitoxHigh affinity formCellular protein synthesisReceptorsLymphocytes